



European Federation of Pharmaceutical
Industries and Associations

29 May 2019

To the Press and to whom it may concern

EFPIA Japan

(European Federation of Pharmaceutical Industries and Associations)

**EFPIA Japan Patient Organization Support Program “PASE”
Third “PASE Awards”: call for entries**

- Patient group activities focused on unsolved challenges in the fields of prevention, diagnosis and treatment -

EFPIA Japan (European Federation of Pharmaceutical Industries and Associations) announces that the third PASE Awards will be implemented as part of the patient advocacy program "PASE (Patient Advocacy Support by EFPIA Japan)". The theme this year is "Patient group activities focused on unsolved challenges in the fields of prevention, diagnosis and treatment". EFPIA Japan now welcomes entries from patient groups, and will offer ¥500,000 to each of the two winners of the "Grand Award".

This year, the third year of the awards, EFPIA Japan sets the above-mentioned theme, focusing on solutions for patient needs in the areas of prevention, diagnosis and treatment, in order to improve daily lives for patients. EFPIA Japan supports patient group activities in Japan and also supports the development of a better medical environment surrounding patients through reflecting the voices of patients appropriately in the health care system.

EFPIA Japan

Marunouchi Kitaguchi Building, 1-6-5 Marunouchi, Chiyoda-ku, Tokyo 100-8265

Tel: +81-3-6301-3066 Fax: +81-3-6301-3060

Third PASE Award Application Guidelines

■ Theme : Patient group activities focused on unsolved challenges aiming to meet unmet medical needs where patients live better in the fields of prevention, diagnosis and treatment

EFPIA Japan set the above-mentioned theme, focusing on solutions for patient needs in prevention, diagnosis and treatment, in order to improve daily lives for patients.

■ Application guideline

1. Qualification requirements:

- ① Being a patient group working for patients in Japan
- ② Being an officially registered non-profit organization such as incorporated association, foundation, NPO, etc.

2. Selection criteria:

- ① Having a clear purpose as a patient group and clear goals with KPIs
- ② Showing concrete deliverables for achieving purpose in past activities
- ③ Having a specific implementation plan of activity for using grants (including how to use grants)
- ④ Being able to cooperate in disseminating the results of activities using grants (Allowing for posting on EFPIA Japan website, notification and reporting on their own website)

3. Requirement for award-winning organizations :

- ① To attend the presentation award ceremony on EFPIA Day (scheduled to be held on September 24, 2019 in Tokyo. There may be media coverage and schedule changes.)
- ② Conduct activities using grants by the end of June 2020
- ③ Submit an activity report (A4 two pages) to EFPIA Japan secretariat by the end of October 2020.

4. Use of Grants:

The financial award should be used for projects with clear implementation plans. It cannot be used to provide cash to individuals or to supplement the working capital



European Federation of Pharmaceutical
Industries and Associations

of a group.

5. Application method :

- ① Please write the items listed below on the application form (free form) and send it to EFPIA Japan Secretariat (info@efpia.jp) in PDF format by July 12, 2019.

6. Contact:

- ① EFPIA Japan Secretariat (info@efpia.jp)

#

■ **Items to be described on application form**

1. Information about the organization

- ① Name of organization (English and Japanese)
- ② Website URL
- ③ Name of person in charge (e-mail address and telephone number)
- ④ List of Board members
- ⑤ Articles of incorporation
- ⑥ Copy of a register
- ⑦ Copy of income statement from previous year

2. Short essay (about 1,500 letters, describing the following 2 points):

- ① Past activities by the organization and deliverables (showing dedication and contribution to patients)
- ② Purpose and implementation plan of activities using grants (including how to use grants)

■ **Selection method**

1. Based on the content of the essay, EFPIA Japan Access Committee selects the top five organizations.
2. The top five organizations will attend the final selection meeting, scheduled to be held at the end of August, and will give a presentation (short essay content) * to EFPIA Japan final selection members

* The presentation time is 5 minutes and up to 3 PowerPoint slides can be used. The presentation language is Japanese or English. We will take 5 minutes of Q&A with the finalists, so a total of 10 minutes per patient group.



European Federation of Pharmaceutical
Industries and Associations

3. The impact of the proposed activities on society and patients' lives, the enthusiasm for the proposed activities, and the answers to questions from the EFPIA members (clarity of points, time management, comprehension, etc.) will be considered, and up to two groups selected as winners of a Grand Award. Grand Prize will be awarded up to 2 consecutive times per group.
4. Up to two selected organizations will attend the EFPIA Day award ceremony and give a presentation at the time of adoption to the media.

■ Procedure after the award

1. Notification of results:

Award-winning organizations will be notified directly by September 3, 2019, and will be posted on the EFPIA Japan website at a later date.

2. Award grants:

We will transfer money by financial institution account transfer.

#

About the EFPIA Japan Patient Organization Support Program “PASE”

“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program established last year with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE was conceived to further encourage patient group activities in Japan, and to support the healthcare environment surrounding patients to evolve, so that it better reflects patients' voices and patient needs. As part of PASE, EFPIA Japan decided to conduct the PASE Awards, in which grants of 1.45 million yen this year will be awarded to organizations that contribute to the evolution of patient advocacy (activities to protect patient rights).

(http://efpia.jp/link/1706_Notifcation_EFPIA_PASE_JP.pdf).

About the Second “PASE Award”

New medicines that give patients hope for treatment are created by sustained investment in innovation¹, and various new drugs approved in Japan have positively changed patients' life. However, due to drastic reform of the drug pricing system in recent years, there is concern that research and development of medicines in Japan is being delayed, which will lead to the re-emergence of the “drug lag”². For the second PASE Award, based on the potential impact on patients due to such environmental changes that year, “patient group activities to protect the environment so that patients can continue to receive better treatment” was selected as an application theme. The second PASE AWARDS invited active patient groups with legal entity status to submit plans between 6 July and 31 August to utilize the PASE grant in Japan. The draft plans were reviewed and selection was based on five evaluation criteria: “contribution to



European Federation of Pharmaceutical
Industries and Associations

healthcare throughout Japan”, “implementation of educational activity on the disease itself and the related countermeasures”, “novelty of the proposed activity compared with past activity performances”, “feasibility of the plan”, and “how important is the PASE grant in the proposed plan”. The two organizations that won the Grand Award were each offered a grant of 500,000 yen and invited to attend the presentation ceremony on 8 November last year. The three groups that won the Honor Award were offered a grant of 150,000 yen.

About the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan

EFPIA Japan, established in April 2002, represents 24 R&D-based European pharmaceutical companies operating in the Japanese market. Combined sales from the EFPIA member companies account for approximately 22% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “contribute to healthcare and patients in Japan through the rapid introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen communication with policymakers for the improvement of Japanese healthcare.

About the European Federation of Pharmaceutical Industries and Associations (EFPIA)

EFPIA, headquartered in Brussels, the capital of Belgium, represents the pharmaceutical industry operating in Europe. Through its direct membership of 33 national associations and 42 leading pharmaceutical companies, EFPIA is the voice of 1,900 companies committed to developing and bringing new treatments to patients around the world that will improve the quality of life.

Details can be found below.

<http://efpia.jp/English/index-e.html> (EFPIA Japan)

<http://www.efpia.eu> (EFPIA)

Inquiries to:

Hitoshi Fujita, Public Relations Committee in charge of PASE, EFPIA Japan

Novartis Pharma K.K.

1-23-1 Toranomon, Minato-ku, Tokyo 105-6333

TEL: 090-9837-4326

Mail: hitoshi.fujita@novartis.com

Miki Okada, Access Committee in charge of PASE, EFPIA Japan

GlaxoSmithKline K.K.

Akasaka Intercity AIR, 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052

TEL : 070-3543-2224

Mail: miki.x.okada@gsk.com



European Federation of Pharmaceutical
Industries and Associations